Ramoni C, Dupuis M L, Cenciarelli C, Ciccolini F, Cianfriglia M
Laboratorio di Immunologia, Istituto Superiore di Sanità, Rome, Italy.
Ann Ist Super Sanita. 1990;26(3-4):433-9.
The using of multidrug-resistant (MDR) cell variants represents one of the major obstacles to an effective cancer therapy based on the administration of cytotoxic compounds. In the present article we describe experimental procedures able to eradicate, in vitro, by using specific immunological reagent, MDR tumor cells. In an allogeneic cell system, natural killer (NK) and lymphokine activated killer (LAK) cells result effective against MDR variants of the human T-lymphoblastoid CEM cell line. Surprisingly effector cells discriminate in their lytic capacity target cells possessing a MDR phenotype. A direct relationship between the degree of relative resistance shown by target cells and cytotoxic level exerted by peripheral lymphocytes stimulated and non by IL-2 was observed. The preincubation of MDR cell variants with a monoclonal antibody (MoAb57) specific for an extramembranal epitope of P-glycoprotein induced, in presence of effector cells, a strong antibody-dependent cell-mediated cytolysis (ADCC). This phenomenon was observed only in MDR variants over-expressing in concomitance with drug-resistance high level of P-glycoprotein. In identical experimental conditions, drug-sensitive parental cells does not show valuable ADCC.
使用多药耐药(MDR)细胞变体是基于细胞毒性化合物给药的有效癌症治疗的主要障碍之一。在本文中,我们描述了通过使用特定免疫试剂在体外根除MDR肿瘤细胞的实验程序。在同种异体细胞系统中,自然杀伤(NK)细胞和淋巴因子激活的杀伤(LAK)细胞对人T淋巴细胞白血病CEM细胞系的MDR变体有效。令人惊讶的是,效应细胞在其裂解能力上区分具有MDR表型的靶细胞。观察到靶细胞显示的相对耐药程度与未用IL-2刺激的外周淋巴细胞施加的细胞毒性水平之间存在直接关系。MDR细胞变体与针对P-糖蛋白膜外表位的单克隆抗体(MoAb57)预孵育,在效应细胞存在下,诱导强烈的抗体依赖性细胞介导的细胞溶解(ADCC)。仅在同时过度表达高水平P-糖蛋白且具有耐药性的MDR变体中观察到这种现象。在相同的实验条件下,药物敏感的亲本细胞未显示出有价值的ADCC。